Share on StockTwits

Pharmacyclics (NASDAQ:PCYC) General Counsel Richard B. Love unloaded 1,500 shares of the stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $124.00, for a total transaction of $186,000.00. Following the transaction, the general counsel now directly owns 204 shares of the company’s stock, valued at approximately $25,296. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Pharmacyclics (NASDAQ:PCYC) opened at 123.95 on Friday. Pharmacyclics has a 1-year low of $82.51 and a 1-year high of $154.89. The stock has a 50-day moving average of $112.2 and a 200-day moving average of $107.7. The company has a market cap of $9.330 billion and a price-to-earnings ratio of 109.97.

Pharmacyclics (NASDAQ:PCYC) last released its earnings data on Thursday, July 31st. The company reported ($0.26) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.23) by $0.03. The company had revenue of $113.00 million for the quarter, compared to the consensus estimate of $95.88 million. During the same quarter last year, the company posted $0.25 earnings per share. Pharmacyclics’s revenue was up 106.6% compared to the same quarter last year. On average, analysts predict that Pharmacyclics will post $0.36 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on PCYC shares. Analysts at William Blair raised their price target on shares of Pharmacyclics from $150.00 to $180.00 in a research note on Tuesday, August 5th. They now have an “outperform” rating on the stock. Separately, analysts at Deutsche Bank reiterated a “buy” rating on shares of Pharmacyclics in a research note on Friday, August 1st. They now have a $180.00 price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Pharmacyclics in a research note on Friday, August 1st. They now have a $152.00 price target on the stock, up previously from $150.00. Three equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Pharmacyclics has a consensus rating of “Buy” and a consensus price target of $155.33.

Pharmacyclics, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.

Receive News & Ratings for Pharmacyclics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmacyclics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.